BTIG Keeps Their Buy Rating on US Foods Holding (USFD)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
According to TipRanks, Saleh is a 5-star analyst with an average return of 11.5% and a 63.98% success rate. Saleh covers the Consumer Cyclical sector, focusing on stocks such as Wingstop, Darden Restaurants, and McDonald's.
US Foods Holding has an analyst consensus of Strong Buy, with a price target consensus of $84.25.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target
Denali Therapeutics, Inc. (NASDAQ:DNLI) is one of the best oversold NASDAQ stocks to buy now. In a report released on July 7, Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics, Inc. (NASDAQ:DNLI) with a price target of $32.00. A doctor examining a patient's brain scan in a hospital setting displaying a neurological disorder. Basing the optimistic rating on the company's promising developments, the analyst reasoned that Denali Therapeutics, Inc. (NASDAQ:DNLI) has made notable developments in its enzyme replacement therapy, DNL-310, which the FDA has accepted for priority review for the treatment of Hunter Syndrome. He stated that therapy is significant for its ability to cross the blood-brain barrier, which may provide considerable advantages over the present treatments. With the FDA's acceptance showing strong regulatory support, the drug may attain an expedited path to the market. The firm also stated that Denali Therapeutics, Inc.'s (NASDAQ:DNLI) broader pipeline, which includes other Transport Vehicle-enabled therapies, also suggests the potential to address various neurological conditions. Denali Therapeutics, Inc. (NASDAQ:DNLI) develops and commercializes product candidates for the treatment of neurodegenerative diseases. Its product portfolio includes LRRK2, RIPK1, TREM2, and Tau. While we acknowledge the potential of DNLI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best oversold NASDAQ stocks to buy now. On July 11, BTIG analyst Julian Harrison maintained a Buy rating on Apogee Therapeutics Inc. (NASDAQ:APGE), raising the price target to $115 from $100. A biotechnologist in a white lab coat manipulating genes in a laboratory. The analyst told investors in a research note that the new EASI-75 watermark for Biologics in Atopic Dermatitis surpassed expectations, supporting a market-leading profile and painting a positive picture for the company. Apogee Therapeutics Inc. (NASDAQ:APGE) has $681.4 million in cash, cash equivalents, and marketable securities as of March 31. Based on the company's current operating plans, management expects its existing cash, cash equivalents and marketable securities to support its operating expenses into the first quarter of 2028. Apogee Therapeutics Inc. (NASDAQ:APGE) is a biotechnology company that offers treatments for chronic obstructive pulmonary disease (COPD), atopic dermatitis (AD), and associated inflammatory and immunology (I&I) indications. While we acknowledge the potential of APGE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Prologis lifts annual FFO forecast as warehouse leasing rebounds
-Warehouse-focused real estate investment trust Prologis on Wednesday raised the bottom of its forecasted range for adjusted core funds from operations in 2025, as customers resumed leasing after U.S. tariffs forced a slowdown in April. Shares of the company rose 2.6% to $111.5 in premarket trading. Although uncertainties around U.S. President Donald Trump's tariffs persist, companies are once again ramping up leasing as they plan inventory for back-to-school and early holiday business. "Our leasing pipeline has reached historically high levels," company President Daniel Letter said on Wednesday. The company now expects adjusted annual core FFO per share between $5.80 and $5.85; it had forecast a range of $5.70 to $5.86 earlier. The fresh forecast is above analysts' expectation of $5.63 per share, according to data compiled by LSEG. The company, which develops and manages warehouses, distribution facilities and fulfillment centers across 20 countries, reported a core FFO of $1.46 per share in the second quarter, compared with analysts' average estimate of $1.41 per share. "We expect further expansion of (Prologis') leasing pipeline, which could signal a recovery in demand if economic growth accelerates," analysts at BTIG wrote in a note ahead of Prologis' quarterly results. The San Francisco, California-based company's total revenue was $2.18 billion for the quarter. Analysts on average had expected a topline of $2.08 billion. Prologis, which operates close to 5,900 facilities worldwide, counts Amazon, Home Depot, FedEx and UPS among its biggest customers, according to its latest annual report.
